PrILUMYA (tildrakizumab injection) is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.10
Please consult the Product Monograph at
http://info.ilumya.ca/Product_Monograph
for important information relating to contraindications, warnings,
precautions, adverse reactions, interactions, dosing and conditions
of clinical use.
The Product Monograph is also available by calling our medical
information department at
1-844-924-0656.